Celgene gets EU panel vote on cancer drug Pomalyst

Celgene gets positive recommendation from EU panel on its multiple myeloma drug Pomalyst

Associated Press

NEW YORK (AP) -- Celgene Corp. said Friday that a regulatory panel in the European Union is recommending that its cancer drug Pomalyst be approved.

Celgene said it expects to get a decision on the drug in two to four months. Pomalyst is intended to treat multiple myeloma, a cancer of the blood, in patients who have not been helped by other cancer drugs. The Food and Drug Administration approved it in February.

Shares of Celgene rose 96 cents to $125.51 in morning trading.